Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Conditions
Interventions
Denikitug
Nivolumab
+2 more
Start Date
April 1, 2026
Primary Completion Date
January 1, 2030
Completion Date
January 1, 2030
Last Updated
April 23, 2026
NCT06340711
NCT05969860
NCT05745857
NCT04895709
NCT05467891
NCT05660083
Gilead Clinical Study Information Center
CONTACT
1-833-445-3230 (GILEAD-0)GileadClinicalTrials@gilead.comLead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions